Résumés
Résumé
L’épissage des pré-ARN messagers constitue une étape obligatoire pour la très grande majorité des transcrits primaires chez les eucaryotes. Il est sujet à de nombreuses variantes, ou épissages alternatifs, qui permettent l’assemblage de transcrits codant pour des protéines requises de manière transitoire ou traduisant une adaptation pathologique. Cette diversification du réservoir de transcrits augmente sensiblement la variabilité protéique. L’identification de mutations dans les séquences nécessaires à l’épissage ou à son contrôle a permis de déterminer les modifications d’épissage en relation avec le développement de maladies héréditaires ou cancéreuses. Rapidement, des approches ont été développées pour tenter de contourner de façon expérimentale l’effet de ces mutations, afin de restaurer un niveau d’épissage suffisant à une compensation fonctionnelle efficace. Les espoirs suscités par ces nouvelles approches méritent que l’on en prenne toute la dimension et que les perspectives thérapeutiques qu’elles offrent soient évaluées.
Summary
Pre-mRNA splicing operates towards at least 95 % of the transcript pool. It is subjected to a large number of variations, collectively regrouped under the term of alternative mRNA splicing, which occurs, on average, 6 to 8 times per pre-mRNA molecule. Consequently, many more proteins may be encoded from a single gene, which may satisfy a physiological need, or mark a pathological adaptation. The identification of mutations in sequences required for splicing, both constitutive and alternative, or for their control, has permitted to determine the causes of qualitative or quantitative variations in transcript levels associated with inherited diseases or cancer development. A number of molecular approaches have been undertaken to try to compensate for the effect of deleterious splicing mutations and to restore, at least in part, sufficient amounts of either the normal or a surrogate transcript. These include overexpression of splicing proteins, improvement of their activity by post-translational modification, splice-site increased or decreased usage, and RNA-mediated trans-splicing. Using such approaches, phenotypic improvements have been obtained in animal models, carrying new hopes for the development of therapeutic strategies aimed at correcting both inherited and acquired diseases that involve pre-mRNA splicing defects.
Parties annexes
Références
- 1. Nilsen TW. The spliceosome : the most complex macromolecular machine in the cell ? BioEssays 2003 ; 25 : 1147-9.
- 2. Caceres JF, Kornblihtt AR. Alternative splicing : multiple control mechanisms and involvement in human disease. Trends Genet 2002 ; 18 : 186-93.
- 3. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003 ; 17 : 419-37.
- 4. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002 ; 18 : 123-7.
- 5. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003 ; 72 : 291-336.
- 6. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001 ; 29 : 2850-9.
- 7. Hanke J, Brett D, Zastrow I, et al. Alternative splicing of human genes : more the rule than the exception ? Trends Genet 1999 ; 15 : 389-90.
- 8. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002 ; 30 : 13-9.
- 9. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes : when nonsense affects RNA abundance. Trends Biochem Sci 1998 ; 23 : 198-9.
- 10. Proudfoot N. Connecting transcription to messenger RNA processing. Trends Biochem Sci 2000 ; 25 : 290-3.
- 11. Logette E, Wotawa A, Solier S, et al. The human caspase-2 gene : alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene 2003 ; 22 : 935-46.
- 12. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense : exonic mutations that affect splicing. Nat Rev Genet 2002 ; 3 : 285-98.
- 13. Brinkman BM. Splice variants as cancer biomarkers Clin Biochem 2004 ; 37 : 584-94.
- 14. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004 ; 22 : 535-46.
- 15. Roberts GC, Smith CW. Alternative splicing : combinatorial output from the genome. Curr Opin Chem Biol 2002 ; 6 : 375-83.
- 16. Yeakley JM, Fan JB, Doucet D, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002 ; 20 : 353-8.
- 17. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003 ; 301 : 836-8.
- 18. Jin P, Fu GK, Wilson AD, et al. PCR isolation and cloning of novel splice variant mRNAs from known drug target genes. Genomics 2004 ; 83 : 566-71.
- 19. Lareau LF, Green RE, Bhatnagar RS, Brenner SE. The evolving roles of alternative splicing. Curr Opin Struct Biol 2004 ; 14 : 273-82.
- 20. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999 ; 18 : 3574-8.
- 21. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994 ; 91 : 484-8.
- 22. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998 ; 51 : 191-200.
- 23. Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997 ; 17 : 444-52.
- 24. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002 ; 18 : 123-7.
- 25. Nissim-Rafinia M, Chiba-Falek O, Sharon G, et al. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000 ; 9 : 1771-8.
- 26. Hofmann Y, Lorson CL, Stamm S, et al. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad SciUSA 2000 ; 97 : 9618-23.
- 27. Wu JY, Tang H, Havlioglu N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog Mol Subcell Biol 2003 ; 31 : 153-85.
- 28. Pilch B, Allemand E, Facompre M, et al. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 2001 ; 61 : 6876-84.
- 29. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003 ; 10 : 120-5.
- 30. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001 ; 98 : 9808-13.
- 31. Andreassi C, Jarecki J, Zhou J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001 ; 10 : 2841-9.
- 32. Wotawa A, Solier S, Logette E, et al. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett 2002 ; 185 : 181-9.
- 33. Solier S, Lansiaux A, Logette E, et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res 2004 ; 2 : 53-61.
- 34. Auboeuf D, Honig A, Berget SM, O’Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002 ; 298 : 416-9.
- 35. Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003 ; 9 : 1009-14.
- 36. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004 ; 306 : 1746-9.
- 37. Skordis LA, Dunckley MG, Yue B, et al. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003 ; 100 : 4114-9.
- 38. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003 ; 10 : 120-5.
- 39. Villemaire J, Dion I, Elela SA, Chabot B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem 2003 ; 278 : 50031-9.
- 40. Celotto AM, Graveley BR. Exon-specific RNAi : a tool for dissecting the functional relevance of alternative splicing. RNA 2002 ; 8 : 718-24.
- 41. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003 ; 9 : 1015-9.
- 42. Rogers CS, Vanoye CG, Sullenger BA, George AL Jr. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest 2002 ; 110 : 1783-9.
- 43. Deidda G, Rossi N, Tocchini-Valentini GP. An archaeal endoribonuclease catalyzes cis- and trans- nonspliceosomal splicing in mouse cells. Nat Biotechnol 2003 ; 21 : 1499-504.
- 44. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosomes. In : Gesteland RF, Cech TR, Atkins JF, eds. The RNA world II. Cold Spring Harbor-New York : Cold Spring Harbor Laboratory Press, 1999 : 525-60.
- 45. Sanford JR, Bruzick JP. Developmental regulation of SR protein phosphorylation and activity. Genes Dev 1999 ; 13 : 1513-8.
- 46. Mistelli T, Spector DL. The cellular organization of gene expression. Curr Opin Cell Biol 1998 ; 10 : 323-31.
- 47. Murray MV. Role of phosphorylation in pre-mRNA splicing. Front Horm Res 1999 ; 25 : 83-100.
- 48. Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. HnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993 ; 63 : 289-321.
- 49. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003 ; 112 : 481-6.
- 50. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001 ; 98 : 42-7.
- 51. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002 ; 277 : 49374-82.